Tagrisso paired with Hutchmed drug clears lung cancer test
pharmaphorum
AUGUST 9, 2022
The data provide proof-of-principle for the use of MET-targeting drugs to offset Tagrisso resistance, and charts a way forward towards regulatory approvals of the combination as an alternative to chemotherapy for these patients. It is AZ’s biggest-selling drug, with sales topping $5 billion last year.
Let's personalize your content